儿童使用标为「临时」或短期装置的结局:儿科机械循环支持机构间登记报告
该研究基于PediMACS登记,纳入2012年9月19日至2016年6月30日期间置入临时心室辅助装置(VAD)的63例患儿,分布于20个中心。中位支持时间15天,出血(29%)和神经功能障碍(24%)最常见,71%获得积极结局。结论指出临时VAD不仅用于短期支持,也用于更长期支持策略。
要点
- 临时VAD占PediMACS全部儿科VAD患者的19%。
- 中位支持时间15天,65%患者支持≥10天。
- 71%患者获得积极结局,心肌病和单心室患者有利结局比例分别为88%和60%。
核心结论
- 历史上归类为「临时」的泵不仅用作短期机械循环支持策略,也用作更长期的支持策略。
- 在这个多机构、高急症、复杂患者队列中,使用「临时」VAD使71%的患者获得积极结局(桥接移植、恢复、耐用装置或存活)。
研究设计与样本
- PediMACS是由美国国立卫生研究院支持的国家登记,收录美国食品药品监督管理局批准的、置入时年龄<19岁的患者使用的VAD(耐用或临时VAD)。
- 纳入2012年9月19日至2016年6月30日期间置入分类为临时VAD的装置的患者。
主要发现
- 临时VAD置入63例患者,分布于20个中心,占PediMACS全部儿科VAD患者的19%。
- 置入时中位年龄为3.7岁(范围<1天至18岁)。
- 基础疾病为先天性心脏病26例(41%),其20例分类为单心室;心肌病25例(40%);心肌炎/排斥12例(19%)。
- 患者以INTERMACS Profile 1为主(51%),10例(16%)既往接受过体外膜氧合支持。
- 中位支持时间15天(范围<1天至227天),41例(65%)支持≥10天。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Historically, the "temporary" or short-term ventricular assist device (VAD) was used only as a quick bridge to recovery for children with an acute process. In the current era, the devices that were originally used for temporary support are now being used to support children for longer durations and for a variety of indications. In this study we aimed to describe the overall use, patients' characteristics and outcomes of "temporary" VAD use in children. METHODS: The Pediatric Interagency Registry for Mechanical Circulatory Support (PediMACS) is a National Institutes of Health-supported national registry for United States Food and Drug Administration-approved VADs in patients <19 years of age at the time of VAD implantation (either durable or temporary VAD). Patients undergoing placement of a device classified as a temporary VAD between September 19, 2012 and June 30, 2016 were included. RESULTS: Temporary VADs were implanted in 63 patients at 20 centers, accounting for 19% of all pediatric VAD patients entered into PediMACS. The median age at implantation was 3.7 (range <1 day to 18) years. The underlying diseases were: congenital heart disease in 26 (41%), 20 of whom were classified as single ventricle; cardiomyopathy in 25 (40%); and myocarditis/rejection in 12 (19%). Patients were predominately Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) Profile 1 (51%), and 10 patients (16%) had previously been supported with extracorporeal membrane oxygenation. Median duration of support was 15 (range <1 day to 227) days, with 41 patients (65%) being on support for ≥10 days. The most frequent adverse events were bleeding (29% of patients) and neurologic dysfunction (24% of patients). Overall, 71% (45) achieved a positive outcome (defined as bridge to recovery [30%], transplantation [17%], alive on device [2%] or transition to durable VAD [22%]). Eighty-eight percent (n = 22) of the cardiomyopathy patients and 60% (n = 12) of the single-ventricle patients achieved a favorable outcome. CONCLUSION: Devices historically classified as "temporary" pumps are being used not only as a short-term mechanical circulatory support strategy but also as a longer term support strategy. In this multi-institutional, high-acuity, complex patient cohort, the use of "temporary" VADs resulted in a positive outcome (bridge to transplant, recovery durable device or alive) in 71% of patients.
引用
- Lorts A, Eghtesady P, Mehegan M, et al. Outcomes of children supported with devices labeled as "temporary" or short term: A report from the Pediatric Interagency Registry for Mechanical Circulatory Support. J Heart Lung Transplant. 2017. PMID: 29174220. doi:10.1016/j.healun.2017.10.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。